Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
BioArctic AB Class B ( ($SE:BIOA.B) ) has provided an update.
At its Annual General Meeting, BioArctic AB resolved to carry forward SEK 889,598,575 without paying dividends for 2024, re-elected its board members, and approved remuneration for them. The meeting also authorized the board to issue new shares and introduced a three-year incentive program for employees, which includes performance-based share units contingent on meeting specific conditions related to shareholder returns, operational targets, and sustainability goals.
More about BioArctic AB Class B
BioArctic AB is a Swedish biopharmaceutical company focused on developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. The company is known for its innovative research and development efforts in the biotechnology sector, aiming to address unmet medical needs in the field of neurodegenerative disorders.
Average Trading Volume: 290,954
Current Market Cap: SEK16.38B
Find detailed analytics on BIOA.B stock on TipRanks’ Stock Analysis page.